🔥 Saturday 14 March 2026 Sat, 14 Mar 2026

A single biotech result reset expectations in minutes, while gold and critical minerals kept investors busy on deals, drilling and funding. The week’s biggest moves came from one trial being stopped, a miner losing altitude after heavy selling, and a U.S. tungsten stock hit hard on risk-off trading.

One stock was suspended, another fell hard on dividend news, and a bank-backed covenant waiver still couldn’t stop selling. Elsewhere, boards leaned into buy-backs and DRP settings as investors weighed cash returns against uncertainty.

Gold names split cleanly this week: one stock rocketed on tangible production progress, while another cratered as selling overwhelmed a big plan. Critical minerals kept drawing attention, but several gap-ups didn’t hold once early buyers took profits.

A brutal clinical trial stop wiped out Immutep, while Adherium surged on faster Remote Patient Monitoring growth. Across the rest of healthcare, investors paid up for proof: accredited tests, enrolled Phase III studies, and signed multi-year contracts.

Tech microcaps swung hard as funding news, contract wins and disclosure issues collided. The biggest falls came where investors saw either forced selling or more cash needs ahead.